Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
16,263
Total Claims
$2.1M
Drug Cost
821
Beneficiaries
$2,549
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-87%
Opioid rate vs peers
0.3% vs 2.2% avg
+81%
Cost per patient vs peers
$2,549 vs $1,411 avg
+63%
Brand preference vs peers
17.3% vs 10.6% avg
Opioid Prescribing
0.3%
Opioid Rate
48
Opioid Claims
$537
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,657 claims · $1.8M
Generic: 12,708 claims · $241K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 159 | $195K |
| Empagliflozin | 133 | $164K |
| Sitagliptin Phos/Metformin Hcl | 141 | $154K |
| Dulaglutide | 137 | $144K |
| Linaclotide | 180 | $114K |
| Sitagliptin Phos/Metformin Hcl | 102 | $100K |
| Empagliflozin/Metformin Hcl | 73 | $75K |
| Semaglutide | 50 | $66K |
| Linagliptin | 64 | $62K |
| Icosapent Ethyl | 114 | $56K |
| Linagliptin/Metformin Hcl | 46 | $56K |
| Insulin Glargine,hum.Rec.Anlog | 131 | $48K |
| Insulin Aspart | 75 | $47K |
| Apixaban | 63 | $39K |
| Semaglutide | 32 | $38K |
Prescribing Profile
Patient Profile
73
Avg Age
52%
Female
1.19
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data